Shikata, K., Ito, S., Kashihara, N., Nangaku, M., Wada, T., Okuda, Y., . . . Sugimoto, K. (2022). Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS‐3150) and sodium–glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase III studies. Wiley.
Chicago Style (17th ed.) CitationShikata, Kenichi, Sadayoshi Ito, Naoki Kashihara, Masaomi Nangaku, Takashi Wada, Yasuyuki Okuda, Tomoko Sawanobori, and Kotaro Sugimoto. Reduction in the Magnitude of Serum Potassium Elevation in Combination Therapy with Esaxerenone (CS‐3150) and Sodium–glucose Cotransporter 2 Inhibitor in Patients with Diabetic Kidney Disease: Subanalysis of Two Phase III Studies. Wiley, 2022.
ציטוט MLAShikata, Kenichi, et al. Reduction in the Magnitude of Serum Potassium Elevation in Combination Therapy with Esaxerenone (CS‐3150) and Sodium–glucose Cotransporter 2 Inhibitor in Patients with Diabetic Kidney Disease: Subanalysis of Two Phase III Studies. Wiley, 2022.